AG-946
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Arms / Cohorts
Experimental, Core Period: Phase 2a:2a: Tebapivat (AG-946) 5 mg
Accepting patients
Experimental, Core Period: Phase 2b:2b: Tebapivat (AG-946) 10mg
Accepting patients
Experimental, Core Period: Phase 2b:2b: Tebapivat (AG-946) 15 mg
Accepting patients
Experimental, Core Period: Phase 2b:2b: Tebapivat (AG-946) 20 mg
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.